关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

March 23rd, 2023

Sirona Biochem Announces Debenture Financing

February 27th, 2023

Sirona Biochem Receives Antiviral Testing Results

January 16th, 2023

Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

January 14th, 2023

Sirona Biochem Shareholder Q&A Webinar

December 30th, 2022

Sirona Biochem Announces 2022 Annual Meeting Results

  • 1
  • 2
  • 3
  • …
  • 25
  • Next Page »

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

Enter your info below to subscribe to our newsletter:
Loading